Pune, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The global dermal fillers market is expected to clock US$ 9.23 Billion by 2030. The global dermal fillers market is driven by rising preference for aesthetic enhancement or correction, fad culture, and increasing influence due to social media proliferation. Additionally, growing research & development in dermal fillers, growing preference for youthful appearance, and introduction of novel fillers, are fueling the market. However, high cost of fillers, risk of undesirable outcomes, increasing awareness about body positivity, and surgical limitations are holding the global dermal fillers market growth.
Request a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/dermal-fillers-market/7756
In Feb 2022, Allergan Aesthetics, an AbbVie company received the U.S. Food and Drug Administration approval for Juvéderm Volbella XC Under Eye Filler
In May 2022, Galderma presented upcoming new portfolio of neuromodulators, fillers, biostimulators, and clinical data at the IMCAS World Congress 2022
In Sep 2021, Galderma and Sofregen Medical Inc. entered into a technical partnership to develop next generation fillers. This partnership focuses on utilizing the power of silk protein for immediate volume restoration and provide structure for tissue strengthening
In Sept 2019, Allergan received U.S. Food and Drug Administration approval for the use of juvederm VOLUMA XC hyaluronic acid gel dermal filler to correct age-related deficit
In May 2020, Galderma Received U.S. Food and Drug Administration approval for Restylane® Kysse. Restylane Kysse is the first hyaluronic acid filler specifically indicated for the lips using XpresHAn Technology. XpresHAn Technology™ products have demonstrated natural-looking results for patients with dynamic facial wrinkles
Dermal fillers market growth is attributed to growing geriatric population. With aging, skin starts to lose collagen which provides structure and strength within the body and also gives elasticity and strength to the skin. Dermal filler reduces facial lines & wrinkles and also provides nourishment to skin keeping it hydrated and youthful. According to the World Health Organization, In 2019 the number of people aged above 60 years and older was 1 billion and is expected to grow to nearly 2.1 billion by 2050. Therefore, growing number of aging population is expected to increase the demand for anti-aging dermal filler, and eventually propel the growth of the market
With aging, the body starts to lose collagen, thus the skin starts to lose its bounce and flexibility, resulting in an aged look. In such cases, dermal fillers play an important role as they fill volume to the skin, make face lines more symmetrical, and plump up cheeks and lips. Dermal fillers are injected under the facial skin to decrease wrinkles & lines, soften creases, restore lost facial skin volume, and/or enhance facial contours. This is deemed as a cost effective cosmetic procedure used to look younger without surgery. It is also used for smile fixation, fixation of aging effects, facial line correction, and scar treatment.
The global dermal fillers market has been analyzed from five different perspectives – Type, Material, Application, End-user, and Region
Browse full report insights here: https://growthplusreports.com/report/dermal-fillers-market/7756
The global dermal fillers market has been segmented into two types:
The temporary & semipermanent dermal fillers are biodegradable and last from 6 months to 1 year. The temporary & semipermanent dermal fillers segment holds the highest share during the forecast period owing to its low cost, easy and non-invasive procedure, and good body compatibility. On the other hand, the market share of permanent fillers is relatively less due to factors such as irreversible outcomes, risk of undesirable results, and high cost. The demand for permanent fillers is higher in developed markets of North America and Western Europe.
Excerpts From ‘By Materials’ The global dermal fillers market based on materials has been segmented into:
Hyaluronic acid is leading the global market in terms of revenue, owing biocompatibility nature, and less cost as compared to other fillers. Hyaluronic acid stimulates the production of collagen which provides nourishment and elasticity to the skin. Additionally, minimally invasive procedures and technological advancement are also contributing to market growth.
The global dermal fillers market based on application has been segmented into:
Nose reshaping/rhinoplasty procedures have the highest market share attributed to prevalence of nasal deformities, increasing cases of nasal obstruction, and increasing aesthetical demand for nose reshaping. Additionally, less recovery time and low-cost procedures as compared to other cosmetic procedures are also contributing to the global dermal fillers market growth.
Excerpts from ‘By Region Segmentation’
The global dermal fillers market has been segmented into:
North America dominated the global dermal fillers market, followed by Asia Pacific. The large share of North America in the global market can be attributed to availability of a multitude of approved dermal fillers, high demand for both invasive and non-invasive aesthetic procedures, and widespread availability of skilled cosmetic surgeons.
The prominent players operating in the global dermal fillers market are:
SCULPT Luxury Dermal Fillers Ltd
Merz GmbH & Co. KgaA
VALUE PROPOSITIONS RELATED TO THE REPORT:
Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
Comprehensive quantitative and qualitative insights at segment and sub-segment level
Covid 19 impact trends and perspective
Granular insights at global/regional/country level
Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
Blanket coverage on competitive landscape
Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
'Business Profile' of Key Players
Request for customization of this research report at: https://growthplusreports.com/inquiry/customization/dermal-fillers-market/7756
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
Carson Daly shares health update after undergoing ALIF back surgery
BCOR vs. FUTU: Which Stock Is the Better Value Option?
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
(Reuters) -Johnson & Johnson has agreed to pay $40.5 million to settle New Hampshire's claims over the company's role in the U.S. opioid epidemic, averting a trial that had been scheduled to begin next week. Thursday's settlement resolves a lawsuit brought in 2018 against Johnson & Johnson and its Janssen Pharmaceuticals unit. New Hampshire accused them of aggressively marketing opioids to doctors and patients, misrepresenting their addictive properties when used to treat chronic pain, and targeting vulnerable groups like the elderly.
Leading Payments Platform Developed For Architects Provides Vital Benefits to AIA Members And AEC Industry Professionals
Warren Buffett’s initial $232 million investment has returned over $7 billion—so far.
The U.S. dollar is on a tear, hitting historic highs against major rivals. Here's how that could add to market volatility.
Starbucks Corp. has named Laxman Narasimhan its new chief executive, The Wall Street Journal reported late Thursday, saying that Narasimhan announced he would step down from Reckitt Benckiser Group PLC on Sept. 30. Narasimhan has been the Anglo-Dutch multinational consumer-goods company's CEO for the past three years. The Journal had reported Narasimhan was in final negotiations to take a senior role at a U.S. company. Starbucks Founder Howard Schultz has served as interim CEO, and the company l
Lululemon Athletica Inc. stock rose 10% Friday to put it on track for its biggest one-day percentage gain in more than two years, after the yoga-wear retailer reported stronger-than-expected quarterly earnings.
NEW YORK (Reuters) -Starbucks Corp on Thursday named Laxman Narasimhan as its next chief executive officer, choosing an executive credited with revitalizing the maker of Lysol disinfectants to undertake a "reinvention" of the world's biggest coffee chain. Narasimhan was CEO of Reckitt, which also makes Durex condoms, Enfamil baby formula and Mucinex cold syrup. Starbucks faces a turbulent period.
Sasha Ivanov told CoinDesk the USDN model uses four tokens to supply liquidity and to help the stablecoin retain its $1 peg.
Boston Properties Inc. (NYSE: BXP) has sold the office building at 601 Massachusetts Ave. NW for $531 million, according to public records, what will almost certainly be a top sale in the District this year. The buyer, MT D.C. Two LLC, is an affiliate of Tokyo-based Mori Trust Co. Ltd. Executives with Boston Properties declined to comment at this time. The publicly traded developer built the $350 million, 479,000-square-foot office building on the site of the former NPR headquarters after securing a 20-year lease with Arnold & Porter LLP, which occupied its space in late 2015.
Style Box ETF report for IWX
(Bloomberg) -- Armando Mejia Sanchez, the head of crude oil at the trading arm of Mexico’s state-owned oil firm Pemex, is retiring, according to people with knowledge of the situation.Most Read from BloombergJeremy Grantham Warns ‘Super Bubble’ in Stocks Has Yet to BurstTrump Documents Bear Hallmarks of Closest-Held US SecretsJapan to Allow Non-Guided Group Tours From SeptemberPowell Abandons Soft Landing Goal as He Seeks Growth RecessionPutin Brings China and India to Russia for War Games Defyi
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Huntington Bancshares (HBAN) have what it takes? Let's find out.
(Bloomberg) -- Broadcom Inc. shares rose the most in three months after the chipmaker gave a strong sales forecast for the current quarter, allaying fears that spending on internet infrastructure is slowing. Most Read from BloombergGlobal Bonds Tumble Into Their First Bear Market in a GenerationLukoil Chairman Ravil Maganov Dies After Falling From Hospital WindowPutin Brings China and India to Russia for War Games Defying USElizabeth Holmes Judge Upholds Conviction in Preliminary RulingStocks De
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does NexPoint Residential Trust Inc. (NXRT) have what it takes? Let's find out.
Raytheon (RTX) is set to provide the AMRAAM Telemetry System, initial and field spares, as well as other production engineering support hardware and activities, apart from manufacturing missiles.
(Bloomberg) -- Oil rose, paring a hefty weekly decline, as OPEC ministers and allies prepare to discuss crude output amid a cloudy outlook for a new Iranian nuclear accord.Most Read from BloombergGlobal Bonds Tumble Into Their First Bear Market in a GenerationLukoil Chairman Ravil Maganov Dies After Falling From Hospital WindowPutin Brings China and India to Russia for War Games Defying USElizabeth Holmes Judge Upholds Conviction in Preliminary RulingStocks Decline on Fed Concerns, European Gas
(Bloomberg) -- British satellite startup OneWeb Ltd. took a $229 million writedown after Russia scuppered its launch plans and took 36 of its spacecraft hostage indefinitely earlier this year. Most Read from BloombergGlobal Bonds Tumble Into Their First Bear Market in a GenerationLukoil Chairman Ravil Maganov Dies After Falling From Hospital WindowPutin Brings China and India to Russia for War Games Defying USElizabeth Holmes Judge Upholds Conviction in Preliminary RulingStocks Decline on Fed Co